Last reviewed · How we verify
NCT05098080
Hutrukin to Analyze Safety and PK in Healthy Volunteers
Phase 1 trial testing Hutrukin in Pharmacokinetics in 24 participants. Completed in 5 April 2024.
24 October 2023
Quick facts
| Lead sponsor | XBiotech, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 10 April 2023 |
| Primary completion | 24 October 2023 |
| Estimated completion | 5 April 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Hutrukin — full drug profile →
- Placebo
Conditions studied
- Pharmacokinetics — all drugs for Pharmacokinetics →
Sponsor
XBiotech, Inc. — full company profile →
Who can join
18 and older, any sex, with Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05098080
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pharmacokinetics
Currently open trials in the same condition.
- NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
- NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
- NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
- NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
- NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting
Other XBiotech, Inc. trials
Trials by the same sponsor.
- NCT06526377 — Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis · Phase 2 · not yet recruiting
- NCT06590090 — Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment · Phase 2 · not yet recruiting
- NCT05363891 — Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis · Phase 2 · completed
- NCT05363917 — Natrunix Versus Methotrexate in Rheumatoid Arthritis · Phase 2 · unknown
- NCT05099510 — Natrunix Safety PK Study in Healthy Volunteers · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05098080 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by XBiotech, Inc.
- Last refreshed: 23 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05098080.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing